MK-2870 explained

MK-2870 or SKB264 is an experimental antibody–drug conjugate. The antibody component is directed against "the trophoblast cell-surface antigen 2 (TROP2), which is overexpressed in many types of solid tumors, coupled to moderate cytotoxic belotecan-derivative through a novel linker which was designed to balance the extracellular stability and intracellular rupture".^{[1] [2] [3]} The drug is developed as a partnership between Merck and the Chinese company Kelun.^[4]

Notes and References

1. Rodon . J. . Li . J. . Xue . J. . Diao . Y. . Xu . Y. . Liu . G. . Rao . C. . Fan . B. . Cheng . Y. . Wang . J. . 514O An open-label, global, first-in-human study of SKB264 in patients with locally advanced or metastatic solid tumors . Annals of Oncology . September 2021 . 32 . S585 . 10.1016/j.annonc.2021.08.1036. free .
2. Ouyang . Q. . Yin . Y. . Song . L. . Yan . M. . Wu . X. . Tong . Z. . Liu . Y. . Wang . X. . Jin . X. . Diao . Y. . Liu . G. . Ge . J. . Li . J. . 380MO SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+)/ HER2-negative metastatic breast cancer (mBC): Results from a phase I/II, single-arm, basket trial . Annals of Oncology . October 2023 . 34 . S337 . 10.1016/j.annonc.2023.09.557.
3. Yin . Yongmei . Wu . Xinhong . Ouyang . Quchang . Yan . Min . Song . Lihua . Liu . YunPeng . Tong . Zhongsheng . Geng . Cuizhi . Wang . Ying . Yu . Guohua . Wang . Xiang . Cheng . Ying . Zhao . Weihong . Li . Qun . Diao . Yina . Liu . Gesha . Ge . Junyou . Li . Jin . Abstract OT1-03-02: Efficacy and safety of SKB264 for previously treated metastatic triple negative breast cancer in Phase 2 study . Cancer Research . 1 March 2023 . 83 . 5_Supplement . OT1–03–02-OT1-03-02 . 10.1158/1538-7445.SABCS22-OT1-03-02.
4. News: Taylor . Nick Paul . Merck trims mushrooming ADC pipeline by pulling out of 2 preclinical Kelun programs . 20 November 2023 . Fierce Biotech.